Our innovative R+D Diagnostics program focuses on the development of novel molecular diagnostic tools through investigator-initiated translational research studies. Using standard techniques, we focus on development of new assays specifically designed to detect validated biomarkers such as EGFR, ALK, ROS, BRCA1, BRAF and others.
As an example of our capabilities in this field, we have developed highly sensitive and specific techniques for pre-treatment detection of the T790M resistance mutation at high frequency in exon 20 of EGFR for lung cancer and can develop other assays or validate existing platforms according to our clients’ needs.
‘Liquid biopsy’ program
We are leaders in the field of non-invasive diagnostic assays using alternative biosources such as serum, plasma and platelets from blood samples. In certain cancers such as lung cancer, lack of sufficient biopsied tumor tissue can make it difficult or impossible to perform vital diagnostic tests. Our blood-based assays not only overcome this challenge, but also offer the possibility of long-term serial monitoring of response in real time and early detection of therapy resistance. Our tests are the first to have the required sensitivity and specificity for immediate incorporation into clinical practice.
The Pangaea team is composed of both prestigious clinical and research professionals and combines expertise in preclinical cancer research with extensive experience in R+D Biomarker Discovery and Drug Development.
In-house and through partnerships we perform comprehensive pathology, molecular biology, in vitro and in vivo techniques:
Mutation analysis in tumor tissue and blood
Gene amplification and translocation testing
MTT proliferation assays
Colony formation, migration and invasion assays
Molecular profiling of cell lines and tissue samples
We have the capacity to work with formalin-fixed paraffin-embedded tumor tissue, fresh frozen samples, serum, plasma, platelets and cytologies.
For further details of our R+D diagnostics program: Contact us